Silence Therapeutics plc, (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today that it was advised on 2 August that on that day Alistair Gray, a Non-Executive Director of the Company bought 3,848 Ordinary Shares at 129.75p.
Following this purchase, Alistair Gray is interested in 3,848 ordinary shares, 0.01% of the issued share capital of the Company.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|
1. |
Details of the person discharging managerial responsibilities (PDMR) / person closely associated |
|||||
|
a) |
Name |
Alistair Gray
|
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position / status |
PDMR – Non-Executive Director
|
||||
|
b) |
Initial notification / Amendment |
Initial notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Silence Therapeutics plc
|
||||
|
b) |
LEI |
213800SSURRJBX85SQ91
|
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary Shares in Silence Therapeutics plc
ISIN for Silence Therapeutics plc Ordinary Shares: GB00B9GTXM62
|
||||
|
b) |
Nature of the transaction |
Purchase of Ordinary Shares in Silence Therapeutics plc
|
||||
|
c) |
Prices(a) and volume(s) |
|
||||
|
d) |
Aggregated information – Aggregated volume – Price |
3,848 Ordinary Shares £4,993 |
||||
|
e) |
Date of the transaction |
2 August 2017
|
||||
|
f) |
Place of the transaction |
London Stock Exchange, AIM
|
||||
